Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
None
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV). The objective is to compare the visual improvement from baseline to month 12, in eyes with PCV treated with Aflibercept monotherapy versus combination …

  • 54 views
  • 10 Jun, 2021
  • 3 locations
None
A Study to Comparing SCD411 and Eylea in Subjects With Wet Age-related Macular Degeneration (AMD)

damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which

  • 4 views
  • 27 Jan, 2021
  • 76 locations
None
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). 687 subjects will be randomized to one of the following treatment arms in …

vascular endothelial growth factor
adjuvant therapy
tipiracil
cancer
oxaliplatin
  • 0 views
  • 07 Sep, 2021
  • 150 locations
None
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: Atezolizumab Bevacizumab

vascular endothelial growth factor
metastatic melanoma
tubal ligation
metastasis
measurable disease
  • 0 views
  • 18 Sep, 2021
  • 1 location
None
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular

  • 0 views
  • 07 Nov, 2021
  • 1 location
None
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.

vascular endothelial growth factor
irinotecan
bevacizumab
vegf
EGFR
  • 369 views
  • 27 Nov, 2021
  • 22 locations
None
Episcleral Brachytherapy for the Treatment of Wet AMD

responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the

  • 64 views
  • 04 Apr, 2021
  • 2 locations
None
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

vascular endothelial growth factor
BRCA2
metastasis
olaparib
cytokines
  • 15 views
  • 21 Mar, 2021
  • 1 location
None
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

, oxaliplatin, anti-VEGF therapy and anti-EGFR therapy (for tumours with wild-type KRAS)); randomized for treatment with TAS-102 (standard-arm) or High Dose Intermittent Sunitinib (700 mg once every 2 weeks

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

Diabetic Retinopathy Clinical Research Network (DRCR.net) has shown that patients that receive ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred PRP are non-inferior

  • 1 views
  • 10 Apr, 2021
  • 1 location